The KATHERINE trial investigated the efficacy and safety of adjuvant T-DM1 vs. trastuzumab in these higher-risk patients, enrolling 1486 patients with HER2+ early breast cancer with residual invasive disease at surgery after neoadjuvant chemotherapy + trastuzumab (additional HER2-targeted agents were permitted) [18]. Here, ERBB2 is linked to breast cancer.